Press Release - SUTUREGARD® Medical, Inc is Presenting at Arab Health
X

SUTUREGARD® Medical, Inc. Blog

 
16Jan

Press Release - SUTUREGARD® Medical, Inc is Presenting at Arab Health

Press Release | | Return|

SUTUREGARD® Medical, Inc is excited to announce that CEO Dan Ladizinsky, MD, will be presenting SUTUREGARD® Medical at Arab Health. Arab Health, which runs January 27 to 30 in Dubai, brings in over 4,250 companies to showcase all the latest innovations in healthcare.

“We are honored to be supported by Business Oregon and out strategic partner, Demetch Inc of Miami Lakes, Florida to attend Arab Health”, says Ladizinsky, “It will be our first time there and we will be able to build on our positive market response at Medica 2019 in Germany”. Arab Health will allow SUTUREGARD® Medical, Inc to meet new customers, showcase the SUTUREGARD® ISR Device, introduce their second product, the HEMIGARD Adhesive Retention Suture Device, and further develop relationships.

For 45 years Arab Health has been at the forefront of innovations in healthcare. With over 55,000 attendees and 159 countries represented at the show, Arab Health continues to host the largest collection of healthcare product manufacturers and service providers.

SUTUREGARD® Medical, Inc is proud to be a representative of the United States and showcase its medical products to “the international market, focusing on the Middle East and North Africa (MENA) region”, says Ladizinsky. SUTUREGARD® Medical and Ladizinsky can be found demonstrating at booth #Z6-G01 in the Dubai World Trade Centre.

Based in Portland, Oregon, SUTUREGARD® Medical, Inc is a private firm that provides surgical equipment for surgeons to provide quality high-tension wound closure on patients around the world. With a wide variety of devices available to surgeons, SUTUREGARD® Medical devices are intended to provide minimal wound trauma and reduce the healing period after surgery, providing better results for patients overall. The firm is funded by the Oregon State University Venture Development Fund, as well as through private allocation of funds.

Related

What is Basal Cell Carcinoma (BCC)?

A basal cell carcinoma (BCC) is one of the most common skin cancers. Every year, there are over 4 mi...

Read More >

What is Squamous Cell Carcinoma (SCC)?

Squamous cell carcinoma (SCC) is the second most common skin cancer. While basal cell carcinoma (BCC...

Read More >

Press Release - Operation Smile

The official collaboration between Operation Smile & SUTUREGARD® Medical Inc. Operation Smile is the...

Read More >

Press Release - SUTUREGARD® Medical, INC. is Presenting at the American Society of Plastic Surgery Annual Meeting

SUTUREGARD® is pleased to announce CEO, Dan Ladizinsky, MD, will be presenting for the second time a...

Read More >

Next Generation Suture Retention Bridges

Suture retention bridges support the primary closure location & reduce the risk of wound dehiscence....

Read More >

No Undermining? Are You Kidding Me?

By: Dan Ladizinsky, MD, CEO, SUTUREGARD Medical, Retired Board Certification in General Surgery, Pla...

Read More >

Prevent and Manage Wound Dehiscence.

Making wound closure easier for surgeons and better for patients.

Contact Us